Vaccibody.com |

September 20, 2018 Vaccibody announces clinical collaboration agreement with Nektar Therapeutics for evaluation of Vaccibody’s personalized cancer neoantigen vaccine in combination with Nektar’s CD-122-biased agonist, NKTR-214

Posted at 10:00h in Uncategorized

Vaccibody AS today announced a new clinical collaboration with Nektar Therapeutics to evaluate Vaccibody’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s CD-122-biased agonist, NKTR-214. VB10.NEO is designed to specifically activate the patient’s immune system to tumour specific antigens, called neoantigens. NKTR-214 is designed to...

August 3, 2017 VACCIBODY ANNOUNCES FILING OF A CLINICAL TRIAL APPLICATION (CTA) FOR CANCER NEOANTIGEN VACCINE VB10.NEO WITH GERMAN REGULATORY AUTHORITY (PEI) AND APPOINTMENT OF MADS BUHL AXELSEN AS CHIEF MEDICAL OFFICER (CMO)

Posted at 11:00h in Uncategorized

Clinical Trial Application for VB10.NEO filed with PEI Vaccibody AS today announced filing of a Clinical Trial Application (CTA) for cancer neoantigen vaccine VB10.NEO with German regulatory authority Paul Ehrlich Institute (PEI). VB10.NEO is a personalized vaccine designed specifically for each patient and the neoantigen mutations...

December 15, 2016 Vaccibody AS Successfully completed Private Placement of NOK 220 million (€ 24 million)

Posted at 08:00h in Uncategorized

Reference is made to the press release published by Vaccibody AS (“Vaccibody” or the “Company”) on 9 December 2016 regarding the contemplated private placement (the “Private Placement”) of new shares (the “Offer Shares”) in the Company. The Board of Directors of the Company is pleased to...

November 22, 2016 QUARTERLY REPORT- 2016 Q3

Posted at 22:58h in quarterly-reports

quarterly-report-vaccibody-2016-3q...

August 29, 2016 QUARTERLY REPORT-2016 Q2

Posted at 23:01h in quarterly-reports

quarterly-report-vaccibody-2016-q2...

August 25, 2016 Vaccibody announces positive results from the phase I part of the clinical trial VB C-01 in patients with high-grade cervical dysplasia and recommendation by the cohort review committee as well as the independent data monitoring board to continue to the expansion phase (IIa)

Posted at 11:51h in Uncategorized

Vaccibody AS today announced that the cohort review committee as well as the independent data monitoring board have completed their review of the interim analysis of the results from the phase I dosing part of the multicentre trial VB C-01. The two committees recommended continuation...

April 18, 2016 Quarterly Report – 2016 Q1

Posted at 10:13h in quarterly-reports

Quarterly report Vaccibody - 2016 Q1...

March 1, 2016 Completion of enrolment according to the study protocol for the phase I part of the VB C-01 study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix

Posted at 16:26h in Uncategorized

Vaccibody AS announced today the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...

February 1, 2016 Vaccibody awarded NOK 20 million (USD 2.3 million) to develop patient-specific therapeutic cancer vaccines

Posted at 12:28h in Uncategorized

Therapeutic vaccine company Vaccibody today announced that it has received a grant up to NOK 20 million (USD 2.3 million) over four years from the Norwegian Research Council ‘s BIA Program to develop therapeutic cancer vaccines based on each patient’s specific neoantigens. Neoantigens are tumour-...

September 14, 2015 Vaccibody AS announces vaccination of first patient in its phase I/IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix

Posted at 05:00h in Uncategorized

Vaccibody AS announced today vaccination of the first patient in its multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). Patients will receive...